Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24090148 | 0.90 | HSD17B10 (0.45) | KDM1AMAPTHDAC6 | |
| SCHEMBL24089905 | 0.89 | KDM1A (0.44) | KDM1AMAPTRXFP1CASR | |
| SCHEMBL24089955 | 0.87 | JUN (0.45) | KDM1AALDH1A1 | |
| SCHEMBL24090111 | 0.86 | KDM1A (0.42) | KDM1AALDH1A1MAPT | |
| SCHEMBL29623296 | 0.86 | MAPT (0.43) | MAPTHDAC6 | |
| SCHEMBL24089963 | 0.86 | MAPT (0.43) | MAPTHDAC6 | |
| SCHEMBL24090107 | 0.84 | TDO2 (0.44) | POLBCASRHDAC6 | |
| SCHEMBL23045330 | 0.84 | KDM4E (0.44) | CASR | |
| SCHEMBL29623225 | 0.84 | KDM4E (0.44) | CASR | |
| SCHEMBL29623172 | 0.84 | TDO2 (0.44) | POLBCASRHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352366-B2 | 2-aminoquinazolinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
| US-20220143020-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20210380598-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143020-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | CNKSR1, HAX1, CRKL | KDM1A 1398/4885ALDH1A2 623/4885ALDH1A1 645/4885 |
| US-20210380598-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | CNKSR1, HAX1, SLC26A3 | KDM1A 1575/4885ALDH1A2 547/4885ALDH1A1 739/4885 |
| US-11352366-B2 | 2-aminoquinazolinone derivative | CNKSR1, HAX1, SLC26A3 | KDM1A 1575/4885ALDH1A2 547/4885ALDH1A1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.